BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, February 18, 2025
Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review
See today's BioWorld Science
Home
» CCT6A drives lung adenocarcinoma progression, study reveals
To read the full story,
subscribe
or
sign in
.
Cancer
CCT6A drives lung adenocarcinoma progression, study reveals
June 12, 2024
No Comments
Lung cancer stands as the second most common cancer worldwide and it is estimated that about 85% of diagnosed cases are non-small-cell lung cancers, with lung adenocarcinoma (LUAD) the most common subtype.
BioWorld Science
Cancer